INTUITIVE SURGICAL INC

Nasdaq: ISRG·Sunnyvale, California·

Price
$437.75
Base IV
$119.53

Valuation snapshot

Above bull case

At $437.75, the price is above even our bull case of $188.38.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$119.53
27% of the price · range $65.24–$188.38
Price vs base case
266% above
$437.75 against $119.53
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has fallen 3.2% since this valuation was struck on 2026-10-27, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $65.24 to bull $188.38. Values per share.

Price against each value

Bear case
$65.24
Price 571% above
No growth
…
—
Base case
$119.53
Price 266% above
Researched bygpt-6-sol
Valuation Oct 27, 2026 · Price as of Nov 16, 2026How we got here

What does Intuitive Surgical do?

Intuitive Surgical provides robotic-assisted platforms and instruments to help surgeons perform minimally invasive procedures and diagnostic biopsies with greater precision and control.

It brought in $11.6B of sales in the 12 months to Sep 2026.

Da Vinci surgical systemNimur at English Wikipedia, CC BY-SA 3.0, via Wikimedia Commons
Industry
Healthcare
Based in
Sunnyvale, California
Trades on
Nasdaq as ISRG

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 26¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 33¢ of every dollar.

  • Making what it sells33¢
  • Research and development13¢
  • Sales, marketing and admin22¢
  • Everything else it takes to operate4¢
  • Tax6¢
  • Left as profit26¢
  • Interest and other income came back in+3¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Intuitive Surgical, and for what?

Intuitive Surgical sells robotic systems for minimally invasive surgery and lung biopsies, mainly through its da Vinci and Ion platforms. It also earns recurring revenue from surgical instruments, accessories, leases, maintenance, training, and support services.

Hospitals, healthcare facilities, healthcare systems, and their surgeons and care teams pay for its systems, supplies, leases, and services.

  • Instruments and accessories

    60%

    Single-use or limited-use surgical tools, staplers, energy products, imaging items, and Ion accessories used during procedures.

  • Systems

    25%

    Sales and leases of da Vinci surgical systems and Ion endoluminal systems, including lease revenue recognized over time.

    Da Vinci surgical systemNimur at English Wikipedia, CC BY-SA 3.0, via Wikimedia Commons
  • Service

    16%

    Installation, repair, maintenance, technical support, monitoring, and other support provided to system customers.

    Da Vinci system maintenance and technical supportImage: Intuitive Surgical
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Mexicali manufacturing facilities — Mexicali, Mexico. Intuitive manufactures a significant majority of its instruments and accessories here, making the site central to recurring product supply.
  • Peachtree Corners campus — Peachtree Corners, United States. The approximately 1.7-million-square-foot campus manufactures surgical systems and adds substantial U.S. production capacity.
  • Shanghai joint-venture facility — Shanghai, China. Intuitive's joint venture manufactures da Vinci systems in Shanghai for the Chinese market.
  • Emmendingen endoscope center — Emmendingen, Germany. The center builds da Vinci endoscopes and performs failure analysis, repairs, and safety checks that support product supply and reliability.
  • Blacksburg Ion manufacturing — Blacksburg, United States. The site manufactures products related to Ion, Intuitive's robotic bronchoscopy platform.
See them on the globe

Intuitive Surgical 2025 Form 10-K

How is the business doing?

Sales grew from $4.4B in 2020 to $10.1B in 2025, about 18% a year.

Running the business leaves about 28¢ of each sales dollar as operating profit, up from 24¢ in 2020.

After paying for its upkeep and new investment, it had $3.6B of cash to spare in the 12 months to Sep 2026.

Sales$10.1B
20162025
Operating margin29%
20162025
Free cash flow$2.5B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Intuitive says it exists to improve minimally invasive care by helping physicians use technology to treat patients with fewer constraints.

“We believe that minimally invasive care is life-enhancing care.”

Minimally Invasive Care | Intuitive

What management says it is working on now:

Worldwide da Vinci procedure growth, FY2026
14%–15%
Intuitive Surgical Q3 2026 Earnings Call Transcript
Non-GAAP gross profit margin, FY2026
68.7%–69.3% of revenue
Intuitive Surgical Q3 2026 Earnings Call Transcript
Da Vinci instruments and accessories revenue per procedure, Beginning Q4 2026 in China and rolling out during the first half of 2027 elsewhere
Decrease approximately 3%–5% after pricing actions are fully implemented
Intuitive Surgical Q3 2026 Form 10-Q
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 22% more than a year earlier. The year before, quarters averaged 21%.

Its operating margin is narrower than a year ago: 19¢ per sales dollar, against 30¢.

Since Oct 2026 the share price has risen 2%, from $428.12 to $437.75.

Bull $188.38Base $119.53Bear $65.24Oct 22Nov 16 · $437.75
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 22, 2026.

Recently

Coming up

  • November 2026

    China pricing changes

    Pricing reductions related to China’s national framework are expected to begin affecting instruments and accessories revenue in November 2026.

    Intuitive Surgical Q3 2026 Form 10-Q
  • First half of 2027

    Extended-use instruments and volume pricing

    The company expects to roll out instruments with longer useful lives and volume-based pricing, subject to required clearances in some markets.

    Intuitive Surgical Q3 2026 Form 10-Q
  • Ongoing from Q3 2026

    Cardiac procedure expansion

    Da Vinci 5 cardiac use has received European certification, opening a larger cleared procedure opportunity as hospitals train surgeons and build clinical experience.

    Intuitive Surgical Q3 2026 Earnings Call Transcript
  • Future court proceedings; date not specified

    Antitrust settlement review

    The proposed settlement of the da Vinci surgical robot antitrust case must receive preliminary and final court approval before it becomes effective.

    Intuitive Surgical Q3 2026 Earnings Release

Our own estimate moved too: the base case went from $121.90 to $119.53 a share between our last two valuations. The biggest reason: Da Vinci procedure growth, third quarter moved from an unreported prior value to 14.0%, as reported in Intuitive Q3 2026 earnings.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Competition and alternatives

    Hospitals and physicians can choose conventional surgery, drug treatment, radiation, or rival robotic systems. More effective or cheaper alternatives could reduce procedure volume, pricing, and revenue.

    From the company's own filingsWould hit how fast sales growIntuitive Surgical 2025 Form 10-K, Item 1A Risk Factors

  2. Regulatory delays or limits

    The company must maintain medical-device clearances and certifications across many markets. Delays, new requirements, or restrictions could postpone launches or limit where products can be sold.

    From the company's own filingsWould hit how fast sales growIntuitive Surgical 2025 Form 10-K, Item 1A Risk Factors

  3. International and China exposure

    Trade restrictions, tariffs, local competition, tender delays, reimbursement limits, and political tensions could reduce demand or raise costs in markets outside the United States, especially China.

    From the company's own filingsWould hit how fast sales growIntuitive Surgical 2025 Form 10-K, Item 1A Risk Factors

  4. Usage-based customer arrangements

    Revenue can fall when customers perform fewer procedures than expected under usage-based leases. Customers may also fail to pay, cancel, return, or upgrade systems, creating revenue and credit risk.

    From the company's own filingsWould hit how fast sales growIntuitive Surgical 2025 Form 10-K, Item 1A Risk Factors

  5. Supply-chain dependence

    Some components come from sole- or single-sourced suppliers, and the company does not hold large inventories. Disruptions, tariffs, or shortages could delay products or increase manufacturing costs.

    From the company's own filingsWould hit how much of each sale it keepsIntuitive Surgical 2025 Form 10-K, Item 1A Risk Factors

  6. Pricing changes and litigation

    Planned lower instrument pricing may reduce revenue per procedure. The company also recorded a $450 million charge for an antitrust settlement that still requires court approval.

    From the company's own filingsWould hit how much of each sale it keepsIntuitive Surgical Q3 2026 Earnings Release

  7. Q3 da Vinci procedure growth slowed from about 0.19 in 2025 to about 0.14 in 2026.

    From our researchWould hit how fast sales growIntuitive Q3 2026 Form 10-Q

Is it a good business?

From 2016 to 2025 it earned between 11% and 17% on its shareholders' equity, a median of 14%.

Over 10 years its operating margin ranged from 24¢ to 35¢ per sales dollar, a median of 30¢. Gross margin ran from 66¢ to 70¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on equity16%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 12%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 2.8% in a year, so each remaining share owns a slightly bigger slice.

What might it be worth?

Net debt is excluded: The reported balance sheet does not yet establish a complete debt figure. The per-share value may change when resolved. No earlier published debt figure is available.

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $437.75. Our put its value between $65.24 and $188.38, with $119.53 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $65.24

Although sales have risen quickly, this case assumes slower growth in procedures and tighter profits as Intuitive keeps spending to expand its business.

Base case, $119.53

After recent sales growth of around one fifth a year, this case assumes continued demand for procedures and equipment, with growth gradually settling down.

Bull case, $188.38

Following strong recent sales and equipment growth, this case assumes newer systems and overseas use keep sales rising quickly while more of each sale becomes available as cash.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 266%

For Intuitive Surgical to be worth today's $437.75, sales would need to grow about 51.2% a year. We assume 14.0%. Over the last 5 years, sales grew 16.1% a year.

−20%0%+20%+40%+60%We assume 14.0%Past 5 yrs 16.1%Price needs 51.2%

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 51.2% a year?

Try your own numbers

We're moderately sure of this range: it scores 60 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $119.53 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average14.0%
  • Operating margin31.0%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$119.53 -72.7%

Build